SCHEMBL20880393

SCHEMBL20880393

Nc1ccccc1/C(=C\C=O)C(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 2/20 0.40
▸ MAPT P10636 6/20 0.39
▸ GAA P10253 1/20 0.39
▸ P2RX1 P51575 1/20 0.39
▸ HSD17B10 Q99714 7/20 0.38
▸ ALDH1A1 P00352 7/20 0.38
▸ CFTR P13569 1/20 0.38
▸ KDM4E B2RXH2 4/20 0.36
▸ TSHR P16473 4/20 0.36
▸ HDAC3 O15379 1/20 0.33
▸ HDAC1 Q13547 1/20 0.33
▸ LMNA P02545 2/20 0.33
▸ MAPK1 P28482 2/20 0.33
▸ TP53 P04637 2/20 0.33
▸ HTT P42858 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ SMN1; SMN2 Q16637 3/20 0.32
▸ NPC1 O15118 2/20 0.32
▸ HPGD P15428 2/20 0.32
▸ RAB9A P51151 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3544272 0.74 ALDH1A1 (0.37) PTGS1MAPTGAAP2RX1HSD17B10
SCHEMBL3544271 0.74 ALDH1A1 (0.37) PTGS1MAPTGAAP2RX1HSD17B10
SCHEMBL4412147 0.73 CES1 (0.48) MAPTP2RX1HSD17B10ALDH1A1TSHR
SCHEMBL9244918 0.71 BCAT2 (0.40) HSD17B10ALDH1A1TSHRHDAC3HDAC1
SCHEMBL9244924 0.71 BCAT2 (0.40) HSD17B10ALDH1A1TSHRHDAC3HDAC1
SCHEMBL3037744 0.71 MAPT (0.50) PTGS1MAPTGAAP2RX1HSD17B10
SCHEMBL30371054 0.71 MAPT (0.50) PTGS1MAPTGAAP2RX1HSD17B10
SCHEMBL14090840 0.69 ALDH1A1 (0.43) PTGS1MAPTGAAP2RX1HSD17B10
Anthranilic Acid SCHEMBL6294674 0.68 MAPT (0.52) PTGS1MAPTGAAP2RX1HSD17B10
SCHEMBL3728578 0.65 MAPT (0.58) MAPTGAAHSD17B10ALDH1A1CFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3088397-B1 COMPOUNDS THAT ABROGATE THE CELL CYCLE G2 CHECKPOINT FOR USE IN THE TREATMENT OF CANCER CANBAS CO LTD (JP) 2019-04-10 — — EP disclosed
Send feedback